Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Horizon Discovery Launches GENASSIST Line of Kits and Reagents for Gene-Editing, utilizing CRISPR Technology

Published: Monday, February 10, 2014
Last Updated: Monday, February 10, 2014
Bookmark and Share
The first products and services from GENASSIST™ enable easier, robust implementation of CRISPR and rAAV gene editing experiments.

The current GENASSIST offering comprises both off-the-shelf reagents for using CRISPR editing technology and a unique kit combination of these reagents to allow customers to generate their own CRISPR-ready cell lines that constitutively express Cas9-nickase. Using such cell lines provides a quick start for customers, enabling them to make further modifications to the cell line more efficiently than if they were starting fresh each time. Horizon is also launching a new service for the design, manufacture and most importantly validation of CRISPR RNA guides, in order to maximize the likelihood that gene editing will occur as expected.  

Dr Darrin M Disley, CEO, Horizon Discovery, commented: “The launch of our first CRISPR kits mark the next stage in Horizon establishing itself as the leader in the gene editing field. Recent advances in gene editing technology, with techniques such as rAAV, ZFN and CRISPR, have had a revolutionary effect on translational genomics. Horizon’s goal is to make these developments accessible to the wider scientific audience, through contract manufacturing, do-it-yourself products and high-end technical support services. As the only company who can offer all of these techniques singularly or in combination we can ensure that researchers, on their own or with our advice, can make an informed choice of which technology or combination of technologies to deploy to gain the correct answer to the biological question being asked.”

“CRISPR and Cas9 technology is making gene editing broadly accessible to researchers,” said Eric Rhodes, Horizon’s VP R&D and CTO. “Our new GENASSIST kits, combined with access to rAAV, ZFN, and CRISPR technologies, give researchers an invaluable suite of tools to determine the function of endogenous gene alterations and their effect on disease and therapeutic responses. We’re also utilizing all three technologies within Horizon to expand on our collection of over 550 X-MAN™ genetically defined cell lines and endogenous pathway reporter cell-based assay kits.”

Horizon plans to launch additional products and services in the near future as part of GENASSIST to further enable researchers working in the gene editing field.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Horizon, Centauri Therapeutics Launch Collaboration
Joint venture creates a differentiated new player in the rapidly growing immuno-oncology market, currently valued at £25 billion.
Thursday, March 03, 2016
Horizon Signs Three Diagnostic Agreements Worth an Initial $3.3 Million
Agreements with three global companies for test development and validation.
Thursday, November 26, 2015
Horizon Launches New E-commerce Platform and Expands UK Headquarters
Key investment includes an integrated web-shop and Enterprise Resource Planning system to support further scale and revenue growth.
Thursday, October 29, 2015
Horizon, Swift Partner on Genomic Reference Standards
Standards to be used to support validation, consistency and accuracy of the panel.
Wednesday, October 28, 2015
Horizon In-licenses Oncology Programme from Servier
License programme with milestone payments of up to £50 million plus royalties on product sales.
Thursday, October 08, 2015
Horizon Enters Licensing Agreement with LakePharma
The terms of the license cover commercial use of a genetically-engineered Chinese Hamster Ovary (CHO) cell line, developed by Horizon and adapted to manufacturing conditions by LakePharma.
Thursday, September 17, 2015
Horizon Enters Bioproduction Cell Line Licensing Agreement with LakePharma, Inc.
LakePharma to take a full commercial license for GS null CHO K1 cell line from Horizon for improved efficiency in biopharmaceutical manufacturing.
Wednesday, September 16, 2015
Horizon, Abcam Sign License and Supply Agreement
Horizon Discovery Group plc and Abcam plc have announced the formation of a license and supply agreement between the two companies.
Wednesday, September 09, 2015
Horizon and Redx Sign Cancer Research Collaboration
Collaboration to progress Redx Pharma plc’s novel pan-RAF inhibitor program towards out-licensing.
Friday, September 04, 2015
CareDx and Horizon Enter into a Collaboration
Horizon’s standards to support proficiency testing of CareDx solid organ transplantation injury monitoring diagnostic assay.
Thursday, June 04, 2015
Horizon Discovery Appoints Mr Grahame Cook as a Non-Executive Director
Grahame brings over 20 years’ experience to Horizon.
Thursday, May 14, 2015
Transgenomic to Incorporate Horizon's Genomic Reference Standards
Horizon to provide human genomic reference standards to assure quality and performance of Transgenomic’s Multiplexed ICE COLD-PCR kits.
Thursday, April 23, 2015
Horizon Discovery & Thermo Agreement
Horizon Discovery Group plc and Thermo Fisher Scientific sign supply and commercialization agreement, which will see Thermo market and distribute Horizon’s X-MAN cell line collection.
Monday, April 20, 2015
Horizon and Partners Awarded Up to £6.2M Funding
Horizon to receive up to £652,000 to expand bioproduction research.
Thursday, March 26, 2015
Horizon Discovery Group plc and ArcherDX Sign OEM Agreement
Horizon’s Reference Materials chosen by ArcherDX to validate its FusionPlex test for non-small cell lung cancer markers.
Tuesday, March 24, 2015
Scientific News
Flowering Regulation Mechanism Discovered
Monash researchers have discovered a new mechanism that enables plants to regulate their flowering in response to raised temperatures.
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Nanoparticles Present Sustainable Way to Grow Food Crops
Nanoparticle technology can help reduce the need for fertilizer, creating a more sustainable way to grow crops such as mung beans.
How Scientists Use DNA to Track Disease Outbreaks
They’re the top questions on everyone’s mind when a new disease outbreak happens: where did the virus come from? When did this happen? How long has it been spreading in a particular country or group of people?
Genetic Risk Factors of Disparate Diseases Share Similar Biological Underpinnings
Penn Institute for Biomedical Informatics and colleagues identify "roadmap" of disease mechanisms to identify candidate drug targets.
Drugs that May Combat Deadly Antibiotic-Resistant Bacteria Uncovered
Study identifies 79 compounds that inhibit carbapenem-resistant Enterobacteriaceae (CRE).
Stem Cells Know How to Unwind
Research led by the Babraham Institute with collaborators in the UK, Canada and Japan has revealed a new understanding of how an open genome structure supports the long-term and unrestricted developmental potential in embryonic stem cells.
HIV Particles Used to Trap Intact Mammalian Protein Complexes
Belgian scientists from VIB and UGent developed Virotrap, a viral particle sorting approach for purifying protein complexes under native conditions.
Childhood Asthma Research Receives $2M
Research into the impact of a child’s upbringing and social and physical environments on the development of asthma will receive $2 million to tackle the condition that affects as many as one in three Canadians.
Growing Stem Cells More Safely
Nurturing stem cells atop a bed of mouse cells works well, but is a non-starter for transplants to patients – Brown University scientists are developing a synthetic bed instead.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!